Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kerkmann

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Dermatology and Therapy|July 2, 2024
Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety ConsiderationsMelinda J Gooderham, Marjolein de Bruin-Weller, Stephan Weidinger, et al.
The Journal of Biological Chemistry|December 14, 2004
Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic cellsMiren Kerkmann, Lilian T Costa, Christine Richter, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|June 27, 2021
Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy StudiesBrian S Kim, Jonathan I Silverberg, Sonja Ständer, et al.
Journal of the American Academy of Dermatology|December 14, 2011
The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label studyAlice B Gottlieb, Robert E Kalb, Andrew Blauvelt, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 6, 2025
Impact of lymphadenectomy rates in the quality assurance program in early ovarian cancer of the AGO Study Group - Real-world observationsPauline Wimberger, Jacobus Pfisterer, Andreas du Bois, et al.
The Oncologist|October 15, 2024
Chemotherapy-induced cognitive impairment and its long-term development in patients with breast cancer: results from the observational CICARO studyAnna Kerkmann, Christian Schinke, Adam Dordevic, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 31, 2023
Quality of therapy in early ovarian cancer: results of the quality assurance program of the AGO Study GroupPauline Wimberger, Jacobus Pfisterer, Andreas du Bois, et al.
The Journal of Dermatology|September 27, 2024
Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalisNatasha Mesinkovska, Brett King, Xingqi Zhang, et al.
Lancet (London, England)|July 25, 2022
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trialKristian Reich, Jacob P Thyssen, Andrew Blauvelt, et al.
Immunotherapy|May 31, 2023
Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms: a plain language summaryKristian Reich, Jacob P Thyssen, Andrew Blauvelt, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Dermatology and Therapy|July 2, 2024
Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety ConsiderationsMelinda J Gooderham, Marjolein de Bruin-Weller, Stephan Weidinger, et al.
The Journal of Biological Chemistry|December 14, 2004
Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic cellsMiren Kerkmann, Lilian T Costa, Christine Richter, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|June 27, 2021
Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy StudiesBrian S Kim, Jonathan I Silverberg, Sonja Ständer, et al.
Journal of the American Academy of Dermatology|December 14, 2011
The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label studyAlice B Gottlieb, Robert E Kalb, Andrew Blauvelt, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 6, 2025
Impact of lymphadenectomy rates in the quality assurance program in early ovarian cancer of the AGO Study Group - Real-world observationsPauline Wimberger, Jacobus Pfisterer, Andreas du Bois, et al.
The Oncologist|October 15, 2024
Chemotherapy-induced cognitive impairment and its long-term development in patients with breast cancer: results from the observational CICARO studyAnna Kerkmann, Christian Schinke, Adam Dordevic, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 31, 2023
Quality of therapy in early ovarian cancer: results of the quality assurance program of the AGO Study GroupPauline Wimberger, Jacobus Pfisterer, Andreas du Bois, et al.
The Journal of Dermatology|September 27, 2024
Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalisNatasha Mesinkovska, Brett King, Xingqi Zhang, et al.
Lancet (London, England)|July 25, 2022
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trialKristian Reich, Jacob P Thyssen, Andrew Blauvelt, et al.
Immunotherapy|May 31, 2023
Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms: a plain language summaryKristian Reich, Jacob P Thyssen, Andrew Blauvelt, et al.
Pageof 7